http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112121051-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112121051-B |
| titleOfInvention | Application of mozavatan in preparation of anti-digestive tract tumor medicine |
| abstract | The invention discloses an application of mozavaptan in preparing an anti-digestive tract tumor medicament, wherein the mozavaptan has the chemical name: the invention discloses a 5- (dimethylamino) -1- [4- (2-methylbenzamide) benzoyl ] -2,3,4, 5-tetrahydro-1H-benzazepine, which is proved by experiments to be capable of inhibiting proliferation of esophageal squamous carcinoma cells KYSE150 and KYSE450, gastric carcinoma cells HGC27 and AGS, inhibiting clone formation of esophageal squamous carcinoma cells and inducing apoptosis. Thereby showing that the mozavatan has obvious inhibition effect on esophageal squamous carcinoma cells. Therefore, the mozavatan can be used as an existing clinical medicament to play roles in preventing and treating tumors. The invention provides a new application of the mozavaptan in tumor treatment and prevention. |
| priorityDate | 2020-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.